ColoSeq Polyposis
General Information
Lab Name
ColoSeq Polyposis
Lab Code
CSQP
Epic Name
ColoSeq Polyposis
Description
ColoSeq™ Polyposis is a paired polyp-germline panel that aims to discover the genetic cause of polyps in patients with unexplained colon polyposis. While many patients with adenomatous polyposis are found to have germline variants in APC, MUTYH and other genes, some patients with polyposis remain unexplained. Constitutional mosaic APC mutations have been described and current germline testing of peripheral blood and saliva has not been adequate to detect mosaic APC mutations. Uniquely, by testing colon polyps and a germline sample, ColoSeq™ Polyposis tests for constitutional mosaic mutations in APC and other genes to look for a common mutation. In a recent series of 28 patients with unexplained adenomatous polyposis, a total of 18 (64%) were found to have constitutional mosaic APC mutations detected in their colon adenomas, often also present at low allelic fraction in their germline sample (9 of 18 mosaic cases)1. ColoSeq™ Polyposis may also be useful for the evaluation of hamartomatous and juvenile polyps, serrated colon lesions and other rare polyposis syndromes.
ColoSeq™ Polyposis includes both a comprehensive pan-cancer germline analysis of 91 genes associated with hereditary cancer syndromes AND a targeted tumor assessment of select somatic and constitutionally mosaic somatic mutations to aid in the identifying the etiology of colon polyposis. The polyp analysis includes microsatellite instability, detection of loss of heterozygosity and BRAF V600E mutation.
ColoSeq™ Polyposis uses next-generation sequencing to detect most mutations in AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDK12, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, CTNNB1, DDX41, DICER1, EGFR, EPCAM, ETV6, FANCM, FH, FLCN, GATA2, GEN1, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RINT1, RNF43, RPS20, RSPO3, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SUFU, STK11, TMEM127, TP53, TSC1, TSC2, VHL, and WT1.
Testing is performed on DNA extracted from two colorectal polyps and a germline sample, using next-generation sequencing to detect somatic and germline variants in genes associated with hereditary colon cancer and polyposis. All exons and flanking intronic sequences are analyzed for all panel genes. Promoters and introns are sequenced for the mismatch repair genes and BRCA1/2. Non-coding variants of uncertain significance are assessed with RNA analysis when certain criteria are met. Select patients may be offered long range sequencing if test results suggest an undetected germline variant in a specific gene. Many patients undergoing paired tumor-germline testing have already undergone a lot of testing, and these assays are intended to provide conclusive results whenever possible.
For an overview of available germline and paired tumor-germline testing for hereditary cancer syndromes, please see: Hereditary Cancer Test Menu: Germline and Paired Tumor-Germline guideline.
Gene | Function/Pathway | Heterozygote Cancer risk* | Associated syndrome | References (PMID) |
AKT1 | AKT signaling | Breast, Thyroid | Cowden-like | 23246288 |
ALK | MYC signaling | Neuroblastoma | Cowden-like | 18724359,28674118 |
APC | WNT signaling |
Colon | Familial adenomatous polyposis | 20301519 |
ATM | Double stranded break repair |
Breast, Pancreatic | Ataxia telangiectasia (recessive) | 16832357, 19781682, 22585167 |
ATR | Double stranded break repair |
Oropharyngeal | Seckel (recessive) | 22341969 |
AXIN2 | WNT signaling |
Colon | Oligodontia-colorectal cancer syndrome | 15042511 |
BAP1 | BRCA1-associated protein complex |
Uveal Melanoma, Mesothelioma | BAP1 Tumor predisposition syndrome | 21874000, 21874003 |
BARD1 | BRCA1-associated protein complex |
Breast, Ovarian | Hereditary breast cancer | 21344236 |
BMPR1A | TGF-beta signaling | Colon | Juvenile polyposis | 20301642 |
BRAF | Serine/Threonine protein kinase | Typically somatic or mosaic only | Typically somatic only, association with MLH1 promoter hypermethylation in colon cancer and Cardiofaciocutaneous syndrome when mosaic | 20301365 |
BRCA1 | BRCA1-associated protein complex | Breast, Ovarian | Hereditary breast and ovarian cancer | 22006311, 2270482, 7545954 |
BRCA2 | Fanconi/BRCA | Breast, Ovarian | Hereditary breast and ovarian cancer, Fanconi anaemia FA-D1 (recessive) | 22006311, 8524414 |
BRIP1 | Fanconi/BRCA | Breast, Ovarian | Fanconi anaemia FA-J (recessive) | 22006311, 17033622, 21964575 |
CDH1 | Cell adhesion | Breast, Gastric | Hereditary diffuse gastric cancer | 20301318 |
CDK4 | Cell cycle | Melanoma | Familial melanoma | 19585149 |
CDK12 | MAP kinase regulation | Breast, ovarian cancer, frequently somatic | Hereditary breast and ovarian cancer | 24554720, 29906450, 24240700 |
CDKN1B | Cyclin-dependent kinase inhibitor 1B | Parathyroid, Pituitary | Multiple endocrine neoplasia, type IV | 37733893 |
CDKN2A | Cell cycle | Pancreatic, Melanoma | Familial melanoma and pancreatic cancer | 19585149 |
CEBPA | Tumor suppressor | Leukemia | Familial AML | 35178345 |
CHEK2 | Double stranded break repair | Breast | Hereditary breast cancer | 11967536 |
CTNNA1 | Beta-catenin, e-cadherin complex | Gastric | Hereditary diffuse gastric cancer | 23208944 |
CTNNB1 | WNT signaling | Typically somatic only | Colon cancer, endometrial cancer, desmoid tumors, colon adenomas | 33115416, 37048063 |
DDX41 | Splicing regulation | Leukemia, MDS | Familial MDS, AML | 26712909, 34723452 |
DICER1 | Tumor suppressor | Wilms tumor, pleuropulmonary blastoma | DICER1 syndrome | 29343557, 28960912, 23625684 |
EGFR | Epidermal growth factor receptor | Lung | Familial lung cancer | 37274482 |
EPCAM | Deletions inactivate MSH2, mismatch repair | Colon, Ovarian, Endometrial | Lynch syndrome | 23938213 |
ETV6 | Transcription factor in hemopoietic regulation | Leukemia, MDS | Familial thrombocytopenia, MDS, acute leukemia | 28555414 |
FANCM | Fanconi/BRCA | Breast | Fanconi anemia (recessive) | 25288723 |
FH | Tumor suppressor | Renal | Hereditary leiomyomatosis and renal cell cancer | 25018647, 11865300, 25004247 |
FLCN | Tumor suppressor | Renal | Birt-Hogg-Dube syndrome. Primary spontaneous pneumothorax. | 12204536, 19659657 |
GATA2 | Transcription factor in hemopoietic regulation | Leukemia, MDS | Familial leukemia, MDS, immunodeficiency | 38660832, 364555197 |
GEN1 | Double stranded break repair | Breast | Hereditary breast cancer | 20512659 |
GREM1 | BMP antagonist | Colon | Hereditary mixed polyposis syndrome | 22561515 |
HOXB13 | Sequence-specific transcription factor which binds preferentially to methylated DNA | Prostate | Familial prostate cancer | 36446039, 34799695, 34059701 |
KIF1B | Tumor suppressor | Neuroblastoma | Hereditary neuroblastoma | 18334619, 24469107, 30859632 |
KIT | Proto-oncogene which encodes a tyrosine-protein kinase that acts as a cell-surface receptor for cytokine KITLG/SCF | Gastrointestinal stromal tumors (GIST), Acute myelogenous leukemia (AML) | Hereditary GIST and AML | 36351335, 35821557 |
LZTR1 | RAS ubiquitination/MAPK signaling | Schwannomatosis | Schwannomatosis, Noonan syndrome | 24362817, 25335490 |
MAX | MYC signaling | Pheochromocytoma, Paraganglioma | Hereditary pheochromocytoma and paraganglioma (parent-of-origin effect) | 21685915, 22452945 |
MBD4 | Mismatch DNA repair | Uveal Melanoma, myelodysplastic disease, colon polyposis | Polyposis, multi-organ tumor predisposition (recessive) | 32239153, 35460607 |
MEN1 | Gene expression regulation | Endocrine | Multiple endocrine neoplasia type 1 | 9215689 |
MET | Tyrosine Kinase receptor | Kidney, Squamous cell carcinomas | Hereditary papillary renal cell carcinoma | 11551094, 9140397, 27330189 |
MITF | Melanocyte inducing transcription factor | Kidney, Melanoma | MITF-related melanoma and renal cell carcinoma predisposition | 24290354, 22012259 |
MLH1 | Mismatch DNA repair | Colon, Ovarian, Endometrial | Lynch syndrome | 20301390 |
MLH3 | Mismatch DNA repair | Polyposis (recessive) | unknown | 30573798 |
MSH2 | Mismatch DNA repair | Colon, Ovarian, Endometrial | Lynch syndrome | 20301390 |
MSH3 | Mismatch DNA repair | Polyposis | Familial adenomatous polyposis 4 (recessive) | 27476653, 35675019, 38243056 |
MSH6 | Mismatch DNA repair | Colon, Endometrial | Lynch syndrome | 20301390 |
MUTYH | DNA repair | Colon (homozygotes) | MUTYH-associated polyposis | 20301519, 21952991 |
NBN | Double stranded break repair | Breast | Nijmegen breakage syndrome (recessive) | 15185344, 9590180 |
NF1 |
MAPK signaling | Optic Glioma, Peripheral Nerve Sheath, Breast | Neurofibromatosis | 2114220, 23165953, 20301288 |
NF2 | Cellular regulation | Acoustic neuromas, Vestibular Schwannomas | Neurofibromatosis 2 | 20301380 |
NTHL1 | Base excision repair | Colon | Polyposis (recessive) | 25938944, 26431160 |
PALB2 | Fanconi/BRCA | Breast, Pancreatic | Fanconi anaemia FA-N (recessive) | 17200668, 17200671, 25099575 |
PDGFRA | Protein tyrosine kinase | GIST | Familial, sporadic GIST | 25975287, 23036227 |
PHOX2B | Tumor suppressor | Neuroblastoma | Hereditary neuroblastoma | 17637745, 28674118 |
PIK3CA | AKT signaling | Breast, Thyroid | Cowden-like | 22729224, 23246288 |
PMS2 | Mismatch DNA repair | Colon, Endometrial | Lynch syndrome | 20301390 |
POLD1 | DNA Polymerase | Colon, Endometrial | Familial polyposis, colorectal cancer | 23263490, 23770608 |
POLE | DNA Polymerase | Colon | Familial polyposis, colorectal cancer | 23263490 |
POT1 | Telomere maintenance | Melanoma, CLL, Sarcoma, Glioma, Colon, Thyroid, Breast | Multi-organ tumor predisposition | 23502782, 24686849, 28853721 |
PRKAR1A | cAMP signaling | Endocrine | Carney complex (recessive) | 4010501 |
PTCH1 | Hedgehog | Basal cell carcinoma, PNET | Nevoid basal cell-carcinoma syndrome | 8681379, 8658145, 20301330 |
PTEN | PI3K/MAPK Signaling | Breast | Cowden syndrome | 20301661 |
RAD51B | Double stranded break repair | Unknown | Hereditary breast and ovarian cancer | 24139550 |
RAD51C | Fanconi/BRCA | Ovarian, Breast | Fanconi anaemia FA-O (recessive) | 22006311, 22538716 |
RAD51D | Fanconi/BRCA | Ovarian, Breast | Fanconi anaemia (recessive) | 21822267, 22415235 |
RB1 | Tumor suppressor | Retinoblastoma, Sarcoma, Melanoma | Hereditary retinoblastoma | 25621664, 22355046, 20301625 |
RECQL | DNA repair | Breast | Hereditary breast cancer | 25915596 |
RET | Receptor Tyrosine Kinase | Endocrine | Multiple endocrine neoplasia type 2 | 20301434 |
RINT1 | DNA checkpoint regulation | Breast, Colon | Multi-organ tumor predisposition | 25050558 |
RNF43 | WNT signaling | Colon | Sessile Serrated Polyposis | 27329244, 27081527 |
RPS20 | Ribosomal protein | Colon | unknown | 24941021 |
RSPO3 | WNT signaling | Typically somatic only | Colon cancer | 29127379, 37048063 |
RUNX1 | Hematopoietic stem cell regulation (transcription factor) | myelodysplastic syndrome and acute myeloid leukemia | RUNX1-familial platelet disorder | 21148331 |
SDHA | Succinate dehydrogenase complex | Pheochromocytoma, Paraganglioma | Hereditary paraganglioma-pheochromoctyoma | 20484225, 21752896 |
SDHAF2 | Succinate dehydrogenase complex | Pheochromocytoma, Paraganglioma | Hereditary paraganglioma-pheochromoctyoma | 20301715 |
SDHB | Succinate dehydrogenase complex | Pheochromocytoma, Paraganglioma | Hereditary paraganglioma-pheochromoctyoma | 11404820 |
SDHC | Succinate dehydrogenase complex | Pheochromocytoma, Paraganglioma | Hereditary paraganglioma-pheochromoctyoma | 11062460 |
SDHD | Succinate dehydrogenase complex | Pheochromocytoma, Paraganglioma | Hereditary paraganglioma-pheochromoctyoma | 10657297 |
SMAD4 | TGF-beta signaling | Colon | Juvenile polyposis | 20301642 |
SMARCA4 | SWI/SNF complex | Ovarian | Hereditary small cell carcinoma of the ovary, hypercalcemic | 24658002 |
SMARCB1 | ATP-dependent SWI/SNF chromatin remodeling complex | Schwannoma, Pediatric Rhabdoid Tumors (Kidney, CNS, Soft Tissue), Meningioma, | Schwannomatosis, rhabdoid tumor predisposition syndrome type 1 | 28109176, 29706634 |
SMARCE1 | DNA repair and replication | Spinal meningioma | Familial spinal meningioma | 23377182 |
STK11 | Tumor suppressor | Breast, Colon, Pancreatic, Gastric, Hamartomas | Peutz-Jeghers syndrome | 20301443 |
SUFU | Hedgehog Signaling | Basal cell carcinoma, medulloblastoma, meningioma, gonadal tumours | Nevoid basal cell-carcinoma syndrome (Gorlin syndrome) | 19533801, 35768194 |
TMEM127 | Tumor suppressor | Pheochromocytoma, Paraganglioma | Hereditary paraganglioma-pheochromocytoma | 20301715 |
TP53 | Cell growth | Breast, Ovarian | Li-Fraumeni syndrome | 22006311,20301488 |
TSC1 | Cell growth | Hamartomas | Tuberous sclerosis complex | 10227394, 9924605, 17287951 |
TSC2 | Cell growth | Hamartomas | Tuberous sclerosis complex | 8825048, 9829910 |
VHL | p53 regulation | Kidney, Neuroendocrine | von Hippel-Lindau syndrome | 20301636 |
WT1 | WT1 transcription factor | Wilms tumor | Wilms tumor | 15150775 |
For information on the tumor-germline paired ColoSeq™ Tumor Panel and ColoSeq Tumor Single Gene assays for unexplained mismatch repair deficiency see ColoSeq Tumor Panel [CSQTP] and ColoSeq Tumor Single Gene [CSQTS].
For previous versions of ColoSeq™ - Lynch and Polyposis Panel, see ColoSeq - Lynch and Polyposis Panel [COSEQ]
References
- Jacobson AL, et al. Utility of adenomatous polyp testing for detection of constitutional mosaic APC mutations in unexplained polyposis patients. Collaborative Group of Americas on Inherited Gastrointestinal Cancer, 2021 Annual Meeting, plenary abstract presentation
- Pritchard CC, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012, 14:357-66. 22658618
- Walsh T, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010, 107:12629-33. 20616022
- Nord AS, Lee M, King MC, and Walsh T. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics 2011, 12:184. 21486468
- Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010, 11:31-46. 19997069
- Li J et al. Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet 2016 May, 5;98(5):830-842. 27087319
Synonyms
AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDK4, CDKN1B, CDKN2A, CEBPA, CHEK2, colon polyposis, constitutional mosaicism, CTNNA1, CTNNB1, DDX41, DICER1, EGFR, EPCAM, ETV6, familial adenomatous polyposis, FANCM, FAP, FH, FLCN, GATA2, GEN1, germline mosaicism, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MLH3, mosaicism, MSH2, MSH3, MSH6, MUTYH, MYH-associated polyposis, NBN, Next-generation sequencing, NF1, NF2, NTHL1, paired tissue testing, paired tumor testing, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2, POLD1, POLE, polyps, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RINT1, RNF43, RPS20, RSPO3, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WT1 Colon cancer
Components
Code | Name |
---|---|
CSQPGS | ColoSeq Genes Sequenced |
CSQPRE | ColoSeq Result |
CSQPIN | ColoSeq Interpretation |
CSQPCH | ColoSeq Clinical History |
CSQPMT | ColoSeq Method |
CSQPDI | ColoSeq Director |
Interpretation
Method
Next-generation sequencing.
This assay sequences all exons, flanking intronic splice site sequences, and select promoter regions of AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, BRAF, BRCA1*, BRCA2*, BRIP1, CDH1, CDK4, CDK12, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, CTNNB1, DDX41, DICER1, EGFR, EPCAM, ETV6, FANCM, FH, FLCN, GATA2, GEN1, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1*, MLH3, MSH2*, MSH3, MSH6*, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2*, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RNF43, RPS20, RSPO3, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SUFU, STK11, TMEM127, TP53, TSC1, TSC2, VHL, and WT1.
Gene introns are also sequenced for genes indicated above with an asterisk (*).
Sequences are aligned to the human genome reference (hg19). Test performed by targeted capture for listed genes followed by next-generation sequencing with Illumina technology. This test was developed and its performance characteristics determined by the University of Washington Department of Laboratory Medicine. It has not been cleared or approved by the US Food and Drug Administration. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.
Reference Range
See individual components
Ref. Range Notes
No mutations detected
Ordering & Collection
Specimen Type
Collection
Two polyp specimens will be requested directly, by UW Laboratory Medicine, from the originating pathology department. In order to facilitate this, a pathology report should be submitted with the test requisition, blood control and other clinical and billing paperwork.
NOTE: This test requires BOTH polyp tissues and a germline specimen (peripheral blood, saliva or normal tissue). Only polyp tissues are required if ColoSeq™ testing on a germline specimen has been done previously at UW Lab Medicine.
1) Two Polyp Tissues:
Polyp specimens will be requested directly, by UW Laboratory Medicine, from the originating pathology department. In order to facilitate this, a pathology report should be submitted with the test requisition, blood control and other clinical and billing paperwork.
If the polyp specimens are being submitted by the ordering provider, tissue samples (FFPE) either (a) slides, OR (b) tissue block are required.
(a) Instructions for slide specimens: 1 slide at 4-micron thickness stained with hematoxylin-and-eosin AND 20 unstained, non-baked slides at 10-micron thickness (a minimum of 10 unstained slides is acceptable). Unstained slides can be on charged or uncharged slides. Note: Sections should contain as much tumor tissue as possible.
(b) Instructions for tissue block specimen: Provide complete tissue block containing tumor tissue. If there is more than one tissue block, please provide the block that has the greatest amount of adenomatous tissue. Tissue block will be returned at completion of testing. Ship at room temperature.
NOTE: If germline MMR testing was performed in a different laboratory, a germline sample should be submitted in addition to polyp tissue.
2) Germline control sample:
BLOOD:
· 10 mL whole blood in LAVENDER TOP EDTA tube.
· Also acceptable: YELLOW TOP ACD tube, purified DNA from peripheral blood or cultured cells.
SALIVA:
· Contact laboratory for validated collection kit.
SKIN BIOPSY:
· Collection and transport: Obtain 2-4 mm punch biopsy of skin sample under sterile conditions and place in transport media (e.g. Alpha-MEM media, RPMI). Transport media can be supplied by the lab; call 206-598-4488 to request. If transport media is not available, the following media are acceptable alternatives if shipping time will not exceed 24 hours: lactated Ringer's solution, viral transport medium, or sterile saline. DO NOT USE formaldehyde, formalin, alcohol, or 5% dextrose, or tissue culture medium buffered with bicarbonate.
CULTURED CELLS:
· (2) T23 or (1) T75 flask (minimum 1-T25 flask).
Forms & Requisitions
Requisition Form and Ordering Instructions:
1. Fill out a Genetics Requisition form
2. Under “Check Test Requested,” check: "ColoSeq™ – Polyposis/CSQP"
Genetics Preauthorization Form (preauthorization is only available for providers who are external to the UW system).
Handling Instructions
Ship specimen at room temperature for overnight delivery. Specimen can be held for up to 7 days before shipping if refrigerated.
Ship specimens to:
UW MEDICAL CENTER
LABORATORY MEDICINE - GENETICS LAB
1959 NE PACIFIC ST, ROOM NW220
SEATTLE, WA 98195-7110
Quantity
requested: Entire sample
minimum: 5 mL whole blood
Processing
Blood: Refrigerate whole blood
Unacceptable Conditions: Frozen or clotted specimens
Stability (collection to initiation of testing): Ambient: 5 days; Refrigerated: 7 days; Frozen: Unacceptable
Purified DNA: Refrigerate DNA specimens. Frozen is acceptable.
Performance
LIS Dept Code
Genetics (GEN)
Performing Location(s)
UW-MT |
Genetics
Attention: Genetics Lab Tel: 206-598–6429 M–F (7:30 AM–4:00 PM) Tel (EXOME only): 206-543-0459 |
Faculty |
---|
Frequency
Results within 4 weeks, once sample arrives in the laboratory.
Available STAT?
No
Billing & Coding
CPT codes
Billing Comments
For additional test/billing information, see following page, CPT codes for Hereditary Cancer Panels (germline and paired).
For pricing information, contact Client Support Services 206-520-4600 or 800-713-5198.
Billing and Insurance Pre-Authorization
We offer insurance pre-authorization services (preauthorization is only done for providers who are external to the UW system).
Email: gpab@uw.edu or call 1-855-320-4869 for more information.
LOINC
Interfaced Order Code
UOW5550